CD4 and neoplasm: The combination of the CD4+-depleting antibody and mGITRL-FP sustained depletion of regulatory T cells and when combined with mGITRL-FP agonist effects on CD8+ T cells, tumor regression occurred without the need for CD4+ T cells.